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The ability of chemical radiation sensitizers such as
misonidazole (MISO) to potentiate certain
chemotherapeutic agents has been recognized for
several years. Anti-tumour agents whose activities
are most effectively enhanced both in vitro and in
vivo by sensitizers include cyclophosphamide,
melphalan and the nitrosoureas (for review see
Millar, 1982; McNally, 1982; Siemann, 1982, 1984).
In vitro experiments of chemopotentiation have
concentrated primarily on exposing cells to the
sensitizer in the absence of oxygen (usually for a
period of 2-4h) prior to treatment with the
chemotherapeutic agent in air. These investigations,
usually referred to as "MISO pre-incubation
experiments" have been performed in attempts to
develop mechanisms of action for the phenomenon
of chemopotentiation (Brown, 1982). Several anti-
tumour drugs have been investigated extensively in
this manner; particularly the alkylating agent
melphalan (Stratford et al., 1980; Roizin-Towle &
Hall, 1981; Taylor et al., 1982). In vitro
combinations of nitrosoureas and MISO, especially
those evaluating the hypoxic cell pre-incubation
effects, have been far more limited (Twentyman,
1980, 1982) despite the large enhancement ratios
which can be obtained when MISO is added to in
vivo therapies incorporating some of the
compounds in this anti-tumour agent class
(McNally, 1982; Siemann, 1982, 1984).
The nitrosoureas represent an important class of
chemotherapeutic agents in the treatment of human
malignancies, particularly brain tumours (Levin &
Wilson, 1976). Consequently, in view of the
substantial potentiation and increased therapeutic
benefits observed when certain nitrosoureas and
MISO are combined, experiments were initiated to
evaluate the possibility of utilizing such combined
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modality therapies in the treatment of brain
tumours. For this purpose the 9L rat brain tumour
model was chosen for study. This system has been
used extensively to model for different treatment
regimens involving nitrosoureas and has provided a
basis for quantitative approaches into the problems
of treating human brain tumours (Wheeler et al.,
1983). Because 1,3-bis(2-chloroethyl)-l-nitrosourea
(BCNU) is one of the most effective agents used to
treat brain tumours, combinations of this
nitrosourea and MISO were evaluated in 9L cells
grown as monolayers in tissue culture or as solid
tumours (Wheeler et al., 1984). The former studies
are the subject of this report.
Exponential and plateau phase 9L culture
experiments (Wheeler, et al., 1983) were performed
2 and 5 days after seeding 3 x 105 cells into 100mm
glass Petri dishes. Cells were exposed to MISO
under aerobic or hypoxic conditions utilizing a
chamber system described in detail elsewhere
(Mulcahy & Dembs, 1983). Briefly the cells were
grown in specially designed glass Petri dishes
consisting of a large and small compartment
separated by a glass septum. Cells were plated in
the large compartment while the sensitizer, at 10 x
the desired concentration, was placed in the small
compartment. The plates were then sealed in
aluminum chambers and degassed as previously
described (Mulcahy & Dembs, 1983). To initiate
MISO exposure the aluminum chambers were tilted
and rotated so that the medium overlying the cells
was mixed with the drug solution maintained in the
small compartment of the dish. In the MISO
cytotoxicity experiments the cells were exposed to
various sensitizer doses at 37°C for 0-5h, then the
chambers were opened and the cells trypsinized. In
the sensitizer preincubation experiments 5.0mM
MISO was administered to cells for 2h at 370C
under hypoxic conditions. Then the chambers were
opened, the medium removed and cells rinsed with
PBS, and fresh medium containing various doses of
BCNU added for a 1 h exposure to the
chemotherapeutic agent. Alternatively, the
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nitrosourea was added directly to the cells upon
opening the chamber. Both procedures resulted in
identical cell survival curves. For aerobic sensitizer
exposures, either the chambers were gassed with air
while otherwise handled as described above or the
cells were treated directly by the addition of the
drugs to Petri dishes and then incubated in a 5%
CO2:95% air atmosphere. For all BCNU exposures
the BME medium was buffered to a pH of 7.2 with
10mM HEPES. MISO was dissolved in Hanks
balanced salt solution. BCNU was initially
dissolved in 100% ethanol and diluted with HEPES
buffered BME just prior to exposure. After
exposure, cells were trypsinized, counted on a
haemocytometer, diluted, and plated into 60mm
Petri dishes containing BME plus 10% NBCS.
Colonies formed by surviving cells were stained
with crystal violet 13-14 days after plating, and
those containing _50 cells were counted.
The effects of treating exponentially growing 9L
cells with different concentrations of MISO under
oxic or hypoxic conditions are shown in Figure 1a.



















exposed under hypoxic conditions. At each
sensitizer dose the longer exposure time (3h) led to
significantly more cell killing than the shorter
exposure time (1 h). Figure lb illustrates the role of
exposure time on MISO cytotoxicity at 0.55 and
5.0mM drug concentrations. As in Figure la, no
killing of aerobic cells was seen even when a 5 h
treatment with 5.0mM MISO was used. Exposing
hypoxic cells to 0.55mM MISO for 0-5h also
resulted in no cytotoxicity, but at a 5.0mM
concentration, cytotoxicity increased with MISO
exposure time such that after 5h cell survival was
reduced to 10-3. These findings, that 9L cells
exposed to MISO show: (i) no aerobic cell
cytotoxicity over the dose and exposure time range
used in the present investigation and (ii) hypoxic
cell cytotoxicity which is both exposure time and
sensitizer dose dependent, are consistent with many
other reports.
Experiments then were performed to evaluate the
enhancing effects of MISO on the response of 9L
cells to subsequent treatment with BCNU. On the
basis of the results shown in Figure 1, cells were
b
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Figure 1 Survival ofexponentially growing 9L cells treated at 37°C either (a) with various doses of MISO for
fixed periods of time or (b) for various periods of time with fixed doses of MISO. Data shown are the
mean+s.e. of 3 experiments. Individual points represent individual determinations. s~~~~~~~~ I I
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exposed to 5.0mM MISO for 2h at 37°C under
aerobic or hypoxic conditions. The cells
subsequently were aerated and treated for 1 h at
37°C with a range of BCNU doses. Exposure of
hypoxic cells to 5.0mM MISO for 2h at 370C
resulted in a reduction in surviving fraction to 0.4-
0.9 (Figures lb, 2a, and 2b). No correction for this
direct cytotoxic effect of MISO was made in
calculating the surviving fractions when MISO
pretreatment was followed by exposure to BCNU.
Figure 2a shows that exposing exponentially
growing aerobic 9L cells to BCNU produced littlc
cell kill at low doses (1-3pgml-1) but led to
exponential cell killing at higher doses (3-
10pg ml-1). A similar dose response curve was seen
when cells were held in hypoxia for 2h prior to
BCNU exposure under aerobic conditions (data not
shown). Pretreating 9L cells under aerobic
conditions with 5.0mM MISO also did not enhance
the cell kill efficacy of BCNU ([l vs *). However
exposure to MISO under hypoxic conditions




(AL). Pretreatment with the sensitizer effectively
removed the shoulder on the BCNU survival curve.
At a cell survival level of 10-2, a DEF of -4.1 was
observed for the combination treatment.
For comparison with exponential phase cultures,
the anti-tumour activity of BCNU administered
alone or in combination with MISO, also was
evaluated in plateau phase 9L cells (Figure 2b). The
clonogenic cell survival curve of these plateau phase
cultures had a somewhat smaller shoulder but
virtually an identical final slope to that seen when
exponentially growing 9L cells were treated (Figure
2b vs Figure 2a). MISO pretreatment was again
only effective at enhancing BCNU cell kill when the
cells were exposed to MISO under hypoxic
conditions (A vs ol). For plateau phase cells, a
combined treatment DEF of -2.5 was observed at
a survival level of 10-2.
The potentiation of BCNU by MISO
pretreatment was more extensive in the exponential
than plateau phase cells (Figure 2a vs Figure 2b).
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Figure 2 Survival of (a) exponentially growing 9L cells or (b) 5-day old 9L plateau cell cultures, pretreated
at 37°C with 5.0mM MISO for 2h in air (E1) or N2 (A) prior to exposure to variable does of BCNU for 1 h
in air. Survival after treatment with BCNU in air without MISO pretreatment also is shown (0). Data points
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survival curves in both cases appears to be the
removal of the shoulder although there is also a
suggestion that MISO pretreatment may have
increased the slope of the exponential component of
the survival curve to a greater extent in exponential
cells than in plateau phase cells. In general, the
current findings are in agreement with data
published previously for the alkylating agent
melphalan (Stratford et al., 1980; Roizin-Towle &
Hall, 1981).
Several possible mechanisms for
chemopotentiation by sensitizers have been
advocated (Brown, 1982; Millar, 1982; Siemann
1982, 1984). These include altered drug
pharmacokinetics, inhibition of potentially lethal
damage (PLD) repair, increased DNA crosslinks
and the depletion of non-protein sulfhydryls. For
the interaction between nitrosoureas and sensitizers
support for the altered pharmacokinetics hypothesis
is strong (Lee & Workman, 1983; Siemann, 1984)
although not all results can be accounted for on the
basis of alterations in nitrosourea decay (Mulcahy
& Dembs, 1983; Siemann, 1984). Inhibition of
drug-induced PLD repair by MISO, a mechanism
supported by in vivo investigations (Siemann &
Mulcahy, 1982), seems unlikely to be of importance
in the potentiation of BCNU activity in the present
studies since 9L cells exhibit no recovery from
BCNU-induced PLD (Rosenblum et al., 1975).
Depletion of intracellular SH levels, while not
explaining chemopotentiation entirely (Brown,
1982), may nevertheless represent a particularly
attractive mechanism for the potentiation observed
when nitrosoureas and MISO are combined because
both agents can act directly on the available
cellular SH pool. MISO metabolism by hypoxic
cells reduces intracellular SH levels by enhancing
the oxidation of glutathione while BCNU inhibits
the regeneration of glutathione by affecting
glutathione reductase. This mechanism could
explain the relationship between nitrosourea
carbamoylating potential and the extent of MISO
chemopotentiation observed (Mulcahy, 1982;
Mulcahy & Dembs, 1983) since nitrosoureas having
the highest carbamoylating activities demonstrate
the greatest glutathione reductase inhibition and
vice versa.
In summary, the present studies evaluated MISO
potentiation of BCNU action in exponential and
plateau phase 9L cells. The results indicate the
removal of the shoulders on the 9L BCNU cell
survival curves by MISO pretreatment under
hypoxic conditions. These data support the
hypothesis that chemopotentiation is at least in part
an hypoxia-mediated phenomenon.
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